[Patients with coronary artery stents: when and how should operations be carried out?].
Nowadays stents are implanted in over 90% of percutaneous coronary interventions. Depending on the type of stent implanted, dual antiplatelet therapy combining a cyclooxygenase inhibitor such as acetylsalicylic acid and an adenosine diphosphate receptor antagonist (thienopyridine) such as clopidogrel is required for 1-12 months. Premature termination of antiplatelet therapy during non-cardiac surgery significantly increases the risk of stent thrombosis and consequently myocardial infarction, whereas continuation of dual antiplatelet therapy during surgery increases the risk of severe bleeding. Accordingly, treatment recommendations have to be based on the individual relative risk. In cases with a high risk for major bleeding during surgery, interruption of antiplatelet therapy may be required, whereas in cases of a high risk of stent thrombosis, both antiplatelet drugs should be continued throughout surgery. Patients on dual antiplatelet therapy should be counseled by a team of anesthesiologists, surgeons and cardiologists, to devise the right point in time for the operation, the best perioperative antiplatelet therapy and the appropriate perioperative monitoring.
Abteilung Innere Medizin III (Kardiologie, Angiologie, Pneumologie), Universitätsklinikum, Im Neuenheimer Feld 410, 69120 Heidelberg, Deutschland. Wolfgang.Rottbauer@med.uni-heidelberg.de
W
W
Rottbauer
H A
HA
Katus
D015906:Angioplasty, Balloon, Coronary; D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects*; D000077144:Clopidogrel; D003299:Cooperative Behavior; D023903:Coronary Restenosis / Q000139:chemically induced*; D004359:Drug Therapy, Combination; D054855:Drug-Eluting Stents; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D033183:Interdisciplinary Communication; D007431:Intraoperative Complications / Q000139:chemically induced*; D008134:Long-Term Care; D010353:Patient Education as Topic; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D012086:Reoperation; D012307:Risk Factors; D013375:Substance Withdrawal Syndrome / Q000209:etiology*; D013988:Ticlopidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin